US · NXL
Nexalin Technology, Inc.
- Sector
- Healthcare · Medical - Devices
- Headquarters
- Houston, TX 77056
- Website
- nexalin.com
Price · as of 2024-12-31
$0.38
Market cap 8.77M
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $27.34 | +7,089.06% |
| Intrinsic Value(DCF) | $0.95 | +149.8% |
| Graham-Dodd Method(GD) | — | — |
| Graham Formula(GF) | — | — |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2010 | |||||
| 2011 | |||||
| 2012 | |||||
| 2013 | |||||
| 2014 | |||||
| 2015 | |||||
| 2016 | |||||
| 2017 | |||||
| 2018 | |||||
| 2019 | |||||
| 2020 | $0.00 | $0.00 | |||
| 2021 | $0.00 | $25.64 | |||
| 2022 | $1.02 | $119.25 | $14,542.85 | $0.00 | $0.00 |
| 2023 | $0.49 | $24.66 | $0.00 | $0.00 | $50.23 |
| 2024 | $2.38 | $27.34 | $0.00 | $0.00 | $0.00 |
AI valuation
Our deep-learning model estimates Nexalin Technology, Inc.'s (NXL) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $27.34
- Current price
- $0.38
- AI upside
- +7,089.06%
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$0.95
+149.8% upside
Graham-Dodd
—
— upside
Graham Formula
—
— upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| NXL | Nexalin Technology, Inc. | $0.38 | 8.77M | +7,089% | +150% | — | — | -2.88 | 5.97 | 130.00 | -2.38 | -9.08 | 6.42 | 78.31% | -4596.14% | -4508.73% | -221.05% | -3380.55% | -193.70% | 0.00 | — | 7.25 | 6.39 | 0.07 | 3175.00% | 5235.00% | -1.00% | -17.98% | -7.21 | -1719.51% | 0.00% | 0.00% | 0.00% | -2.38 | -4.68 | 109.37 | -9.04 |
| CLGN | CollPlant Biotechnologies… | $0.57 | 7.18M | +8,539% | +137% | — | +21,233% | -2.30 | 2.84 | 74.26 | -1.89 | -1.72 | 2.87 | -417.09% | -3349.71% | -3225.05% | -79.46% | -364.64% | -62.87% | 0.23 | -1014.76 | 4.44 | 4.21 | 0.57 | 13387.00% | -9530.00% | 29214.00% | -38.11% | -4.75 | -308.10% | 0.00% | 0.00% | 0.00% | -1.71 | -2.02 | 57.12 | -6.47 |
| ENLV | Enlivex Therapeutics Ltd. | $1.15 | 27.95M | — | — | — | — | -1.63 | 1.03 | — | -0.09 | — | 1.03 | 0.00% | — | — | -55.95% | -720.93% | -46.54% | 0.02 | -1195.08 | 6.84 | 6.56 | 0.19 | -5321.00% | — | -4482.00% | -53.71% | -3.42 | -608.40% | 0.00% | 0.00% | 12.23% | -0.09 | -0.10 | — | -3.74 |
| HBIO | Harvard Bioscience, Inc. | $0.61 | 27.44M | +5,740% | -46% | — | +242% | -2.88 | 0.56 | 0.38 | -51.62 | -1.16 | -8.67 | 58.18% | -6.60% | -13.18% | -18.19% | -5.77% | -9.40% | 0.70 | -1.94 | 0.82 | 0.35 | -27.40 | 24783.00% | -1614.00% | -11556.00% | -5.11% | 0.03 | -1.69% | 0.00% | 0.00% | 0.00% | -12.25 | -41.74 | 0.81 | -0.92 |
| IINN | Inspira Technologies Oxy … | $0.58 | 13.97M | — | — | — | — | -1.42 | 3.64 | — | -1121.82 | — | 3.64 | 0.00% | — | — | -219.74% | 7.39% | -127.19% | 0.58 | — | 2.02 | 1.71 | 234.68 | -9994.00% | — | -426.00% | -60.68% | -2.78 | -6254.43% | 0.00% | 0.00% | 0.00% | 1104.79 | -1.31 | — | -8.52 |
| MODD | Modular Medical, Inc. | $0.25 | 15.64M | — | — | — | — | -1.66 | 1.83 | — | -1.09 | — | 1.83 | 0.00% | — | — | -131.58% | -459.49% | -115.69% | 0.05 | — | 10.69 | 10.41 | 0.71 | -3462.00% | — | 1636.00% | -58.31% | -12.43 | -439.34% | 0.00% | 0.00% | 13.57% | -1.00 | -1.04 | — | 2.40 |
| RBOT | Vicarious Surgical Inc. | $2.04 | 13.19M | — | — | — | — | -0.87 | 1.17 | — | -0.32 | — | 1.17 | 0.00% | — | — | -87.40% | -511.76% | -67.41% | 0.30 | — | 6.74 | 6.40 | -0.07 | -2658.00% | — | -2163.00% | -91.59% | -6.52 | -385.51% | 0.00% | 0.00% | 0.00% | -0.29 | -0.39 | — | -4.95 |
| SCYX | SCYNEXIS, Inc. | $0.75 | 31.47M | +6,873% | -20% | — | +4,875% | -2.21 | 0.85 | 12.54 | -0.21 | — | 0.85 | 100.00% | -990.84% | -568.29% | -33.25% | -288.55% | -19.44% | 0.30 | -14.53 | 3.00 | 2.89 | -0.01 | -13165.00% | -9733.00% | -13991.00% | -51.13% | -1.00 | -186.64% | 0.00% | 0.00% | 0.00% | -0.11 | -0.16 | 1.05 | -5.70 |
| XCUR | Exicure, Inc. | $3.74 | 23.84M | — | +24% | — | — | -7.29 | 10.45 | 141.51 | -7.25 | — | 10.45 | 100.00% | -2446.40% | -1940.20% | -197.92% | -269.46% | -72.84% | 0.88 | -679.56 | 4.45 | 4.24 | 0.74 | -2464.00% | — | -7190.00% | -4.11% | -0.95 | -64.10% | 0.00% | 0.00% | 17.56% | -5.25 | -22.06 | 128.36 | -15.21 |
About Nexalin Technology, Inc.
Nexalin Technology, Inc., a medical device company, designs and develops neurostimulation products for the treatment of mental health in the United States and China. It licenses and markets Nexalin Device, a non-invasive and drug-free therapy for the treatment of anxiety and insomnia. The company's Nexalin device emits a patented frequency-based waveform, which stimulates a positive response from the mid-brain structures associated with various mental health disorders. It also engages in the development of Generation 2, a medical device that is in clinical trials for the treatment of substance abuse issues related to opiates, chronic pain, Alzheimer's disease, and dementia. The company was incorporated in 2021 and is headquartered in Houston, Texas.
- CEO
- Mark White
- Employees
- 6
- Beta
- 4.00
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($0.95 ÷ $0.38) − 1 = +149.8% (DCF, example).